Fewer Biotech-Pharma M&As But Tie-ups Indicate New China Trends

The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.